Načítá se...
A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective
There have been 2040 laboratory-confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) in 27 countries, with a mortality rate of 34.9 %. There is no specific therapy. The current therapies have mainly been adapted from severe acute respiratory syndrome (SARS-CoV) treatments, incl...
Uloženo v:
| Vydáno v: | J Med Microbiol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Microbiology Society
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7079582/ https://ncbi.nlm.nih.gov/pubmed/28855003 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1099/jmm.0.000565 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|